Black Diamond Therapeutics, Inc.
BDTXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Black Diamond Therapeutics, Inc. (BDTX) is listed under Biotechnology. With a market capitalization of $97.1M, it sits in micro-cap territory. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma.
Market Cap
$97.1M
Beta
3.33
P/E (TTM)
—
P/E (Fwd)
-1.69
EPS (TTM)
$-0.67
EPS (Fwd)
$-1.00
ROE
-37.2%
ROA
-19.1%
Cash
$110.5M
Total Debt
$17.0M
Free CF
-$23.6M
52W Change
-57.2%
Annual Financials
Cash vs Debt
Where BDTX stands vs its 150-day and 200-day moving averages
As of the September 30, 2026 close, BDTX finished 15.00% below its 150-day moving average ($2.20) and 17.98% below its 200-day moving average ($2.28). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BDTX overbought or oversold?
At the September 30, 2026 close, BDTX's RSI(14) was 29.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $110.5M in cash comfortably exceeding the $17.0M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$23.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -37.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta above 1.5, BDTX tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Black Diamond Therapeutics, Inc.'s trajectory.